Molecular test speeds up colon cancer diagnosis

Why we write about this topic:

Cheaper and innovative solutions in healthcare can help improve life quality in poorer countries.

A diagnostic test, developed by experts at the University of Nottingham, will speed up the diagnosis of colorectal cancer in patients ensuring they receive treatment more effectively, potentially saving thousands of lives, informs the University in a press release.

Based on research developed by scientists at the University, an IP license has been translated by a start-up company called PathGen Diagnostik Teknologi in collaboration with Bio Farma, to develop an affordable molecular diagnostic kit for patients with colorectal cancer (CRC) in Indonesia, called BioColoMelt-Dx.

Improving survival rates

Every year, more than 35,000 cases of CRC occur in Indonesia. Around 35 percent of CRC are in patients younger than 50. They have a poorer outcome, and many cases may be inherited. Management of CRC is by surgery, but up to 50 percent will also require chemotherapy. Precision treatment in these cases is vital to improving survival rates.

Dr. Susanti Susanti and Professor Mohammad Ilyas from the School of Medicine at the University of Nottingham established the Nottingham-Indonesia Collaboration for Clinical Research and Training (NICCRAT) in 2019, with the aim of developing research partnerships with several Indonesian research institutions.

This new test is the result of this research. It is cheap and easy to use and will potentially save thousands of lives, as it allows more precise and effective treatment of CRC while preventing the side effects of unnecessary treatment. It will also determine if the patients have inherited Lynch Syndrome (LS).

CC Diagnostics on its way to European certification with new cervical cancer test

Things are going well for CC Diagnostics. The start-up from the Dutch city of Groningen is developing a new test for cervical cancer.

Early diagnose

LS is a hereditary type of CRC that is associated with a younger age of patients with CRC. Detecting LS has been long reported to be a cost-effective strategy to provide aid in the diagnosis or management of the individual or at-risk family members by implementing appropriate surveillance for early diagnosis of associated cancers.

The test will now allow the families of patients who may share the same genetic condition to be monitored earlier, to detect and potentially prevent cancer.